Jun Zhou

Dr. Jun Zhou


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2023 in Cells & Development
Verified
Journal Article
Closed access
JZJun Zhou
Jun Zhou
MBMichael Boutros
Michael Boutros

15 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
FPFillip Port
Fillip Port
MBMartha A. Buhmann
Martha A. Buhmann
JZJun Zhou
Jun Zhou
MSMona Stricker
Mona Stricker
AVAlexander Vaughan-Brown
Alexander Vaughan-Brown
MBMichael Boutros
Michael Boutros
CRISPR nuclease-mediated gene knock-out is limited by suboptimal sgRNAs, inaccessible target sites, and undesired repair outcomes. Here, we present a Cas12a-based system in Drosophila that targets each gene with four sgRNAs to overcome these limitations. Multiplexed sgRNAs act through redundancy and synergism, frequently creating deletions between target sites and increasing the fraction of loss-of-function mutations. We show that multiplexed gene targeting is well tolerated and does not cause widespread proximity effects. To visualize CRISPR-nuclease activity in living animals, we developed a screening assay and used it to assess Cas12a activity across 33% of the Drosophila genome in combination with over 2000 sgRNAs. This revealed remarkably high on-target (>99%) and very low (<1%) off-target activity of multiplexed Cas12a sgRNA arrays. Quantitative side-by-side comparisons with current Cas9-based systems targeting over 100 genes in parallel demonstrate that multiplexed Cas12a gene targeting achieves superior performance and reveals phenotypes missed by established methods. The system described here provides a framework for reliable gene knock-out in multicellular systems.

3 February 2026 in EMBO Reports
Verified
Journal Article
Open access
PDF file
GPGuofan Peng
Guofan Peng
SYShichao Yang
Shichao Yang
YZYuexia Zhang
Yuexia Zhang
YZYu Zhao
Yu Zhao
XHXiaoyun Huang
Xiaoyun Huang
JZJun Zhou
Jun Zhou
The Drosophila Toll/NF-κB pathway has been extensively studied for its roles in innate immunity and embryonic development. Nevertheless, the regulatory mechanisms underlying Spz/Toll signaling in non-immune contexts remain poorly understood. Here, we demonstrate a critical role for Toll in regulating intestinal stem cell activity through direct transcriptional control of PI3K and Akt in an insulin-independent manner. Time-series transcriptomic analysis of intestinal damage and repair responses reveals that the stress-responsive factor Jumu regulates Spz expression to activate Toll signaling. Disruption of the Jumu/Spz/Toll cascade or PI3K/Akt signaling impairs intestinal regeneration and suppresses tumor growth, and epistasis analysis confirms that PI3K/Akt functions downstream of Toll . Our findings elucidate an autocrine Spz/Toll-mediated mechanism that drives stem cell function via the PI3K/Akt pathway during tissue homeostasis and uncover a critical non-immune role of Toll signaling in both physiological and pathological contexts.

18 August 2026 in Cell Reports Medicine
Verified
Journal Article
Open access
YSYujie Sun
Yujie Sun
YZYu Zhao
Yu Zhao
KHKang Han
Kang Han
WHWulong Hu
Wulong Hu
GPGuofan Peng
Guofan Peng
JZJinhai Zheng
Jinhai Zheng
Colorectal cancer (CRC) is one of the most prevalent malignancies globally. Recent breakthrough of synthetic biology stimulates the utilization of engineered bacteria for cancer diagnosis and treatment. We perform a comprehensive fecal metabolomic analysis in CRC mouse models and patients and identify ornithine as a specific metabolic biomarker for tumor development. We subsequently engineer an E. coli Nissle 1917 (EcN)-based bioluminescent reporter via ornithine-responsive tumor detection. For therapeutic intervention, we construct a probiotic system that locally releases Dickkopf 3 (DKK3), a potent Wnt signaling antagonist to retard tumor growth. Oral administration of the bacteria demonstrates reduced tumor burden and improved survival outcomes in multiple preclinical models, and the anticancer efficacy is further confirmed in CRC patient-derived organoids and patient-derived xenograft (PDX) model. Taken together, we develop a novel probiotic platform combing non-invasive diagnostic capability with targeted therapeutic delivery for CRC management, underscoring the strong potential for clinical translation and eventual application in preventive oncology.

20 October 2026 in Cell Reports
Verified
Journal Article
Open access
YZYu Zhao
Yu Zhao
YSYujie Sun
Yujie Sun
XZXiaofeng Zhu
Xiaofeng Zhu
WHWulong Hu
Wulong Hu
SCSifeng Chen
Sifeng Chen
JZJun Zhou
Jun Zhou

10 November 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SYShichao Yang
Shichao Yang
JHJiahui Huang
Jiahui Huang
CLChangsheng Luo
Changsheng Luo
GPGuofan Peng
Guofan Peng
KZKe-wei Zheng
Ke-wei Zheng
JZJun Zhou
Jun Zhou
Stem cells proliferate rapidly to maintain tissue turnover during regeneration, yet the mechanisms preventing hyperproliferation remain unclear. Here, we identified nuclear factor Y (NF-Y) as a transcriptional repressor that maintains intestinal stem cell (ISC) quiescence. NF-Y restricts ISC proliferation by occupying the promoters of epidermal growth factor receptor (EGFR) signaling components, including Egfr , Mkp3 , Raf , Ras , and pnt , through regulation dependent on the histone acetyltransferase Nejire (Nej)/p300. Loss of NF-Y enhances ISC proliferation and accelerates tumor progression. NF-Y acts with Nej to restrict Egfr expression and suppress hyperproliferation. Together, these results demonstrate that NF-Y, acting with Nej, serves as a key transcriptional repressive brake that restrains growth-signaling to control stem cell activity under homeostatic and disease conditions.